SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 247 filers reported holding SAGE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.22 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $309,708 | -52.5% | 15,049 | +8.4% | 0.04% | -49.4% |
| Q2 2023 | $652,622 | +17.3% | 13,880 | +4.7% | 0.08% | +11.3% |
| Q1 2023 | $556,320 | +126.2% | 13,258 | +105.6% | 0.07% | +121.9% |
| Q4 2022 | $245,952 | +12.3% | 6,449 | +15.1% | 0.03% | +3.2% |
| Q3 2022 | $219,000 | +3.8% | 5,601 | -14.3% | 0.03% | +10.7% |
| Q2 2022 | $211,000 | -76.8% | 6,533 | -76.2% | 0.03% | -73.3% |
| Q1 2022 | $908,000 | +261.8% | 27,424 | +365.4% | 0.10% | +262.1% |
| Q4 2021 | $251,000 | +10.1% | 5,893 | +14.5% | 0.03% | 0.0% |
| Q3 2021 | $228,000 | -0.4% | 5,148 | +27.9% | 0.03% | -3.3% |
| Q2 2021 | $229,000 | -79.1% | 4,026 | -72.6% | 0.03% | -82.1% |
| Q1 2021 | $1,098,000 | +425.4% | 14,669 | +506.7% | 0.17% | +265.2% |
| Q4 2020 | $209,000 | +260.3% | 2,418 | +588.9% | 0.05% | -6.1% |
| Q4 2017 | $58,000 | – | 351 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sio Capital Management, LLC | 179,200 | $29,516,000 | 16.65% |
| TRV GP II, LLC | 547,916 | $90,247,000 | 16.25% |
| Opus Point Partners Management, LLC | 71,000 | $11,694,000 | 10.12% |
| Casdin Capital, LLC | 250,000 | $41,178,000 | 10.03% |
| RA Capital Management | 455,173 | $74,972,000 | 6.27% |
| Crawford Lake Capital Management, LLC | 154,278 | $25,411,000 | 6.00% |
| Palo Alto Investors LP | 810,806 | $133,548,000 | 5.75% |
| GREAT POINT PARTNERS LLC | 200,000 | $32,942,000 | 5.62% |
| BB BIOTECH AG | 1,042,439 | $171,700,000 | 4.84% |
| Crawford Lake Capital Management, LLC | 92,300 | $15,203,000 | 3.59% |